The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
For full access to this article login to GEN Select now.
Reformulations Must Provide Added Value
Novel Drugs Must Really Improve on the Original; Dosing Convenience Alone Is Not Enough
- Reformulating currently marketed pharmaceuticals is a common way to both improve drug performance and manage the life cycle of a brand. In the past, it was often sufficient for commercial success to develop only a more convenient dosing regimen, such as once-daily oral dosing from twice-daily oral dosing. ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.